Medical management of gastric cancer: A 2014 update

Elimova, Elena; Shiozaki, Hironori; Wadhwa, Roopma; Sudo, Kazuki; Chen, Qiongrong; Estrella, Jeannelyn S.; Blum, Mariela A.; Badgwell, Brian D.; Das, Prajnan; Song, Shumei; Ajani, Jaffer A.

doi:10.3748/wjg.v20.i38.13637

Cited by 37 publications

(34 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, although patients may present the same tumor stage, they often differ in natural cancer history and response to oncological or surgical treatment, for example [2]. Therefore, differences in already known clinicopathologic and prognostic features seem to explain the heterogeneity of clinical situations in many cases [3]. In addition, GC may diverge from the outcome predicted, suggesting that other unknown underlying pathogenetic (both genetic and epigenetic) mechanisms could be involved.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, GC may diverge from the outcome predicted, suggesting that other unknown underlying pathogenetic (both genetic and epigenetic) mechanisms could be involved. Filling these knowledge gaps is desperately needed in order to improve the survival of GC patients [3]. With this purpose, we decided to collect the gastric lavage (GL) of GC patients for cytopathologic analysis and immunometric study of four tumor markers (CEA, CA 19.9, CA 72.4, and CA 50).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50

Virgilio¹,

Giarnieri²,

Montagnini³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

Objectives: To investigate gastric lavage (GL) cytopathology and immunometric analysis as novel clinicopathologic and prognostic parameters for gastric cancer (GC). Study Design: In 38 patients with gastric adenocarcinoma, we performed a cytopathologic analysis and an immunometric assay of GL using four tumor markers (CEA, CA 19.9, CA 72.4, and CA 50). The intragastric tumor marker levels were compared with a control group consisting of 41 non-GC patients to determine a statistically significant cutoff value. Results: GL cytopathology demonstrated the presence of cancer cells in 13 (34.2%) of the 38 GC patients: such a finding correlated to the parameters pT and pN with a statistically significant validity (p < 0.0267 and p < 0.0306, respectively). Measurement of intragastric CA 19.9 and CA 50 attained a statistically significant cutoff value (p < 0.002 and p < 0.0096, respectively), which was invalidated by the low sensitivity of the ROC curve analysis. Conclusions: In contrast to determination of its tumor markers, GL cytopathology correlated well with pT and pN staging parameters. Should this and other features be corroborated by future studies, the GL cytology test could be routinely used to detect aggressive types of GC even at early stages and result in important progress in the knowledge, staging, prediction, as well as management and follow-up of this inauspicious type of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50

Virgilio¹,

Giarnieri²,

Montagnini³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…11 Mortality rates for both gastric and colorectal cancer decline in the past decade attributed to the prevention, early detection, and treatment, 12 but gastric cancer and colorectal cancer still rank the second and fourth leading cause of cancer deaths worldwide. 13,14 A number of studies have investigated the association between expression of cyclin E and survival in patients with gastric and colorectal cancer. However, whether cyclin E represents a prognostic biomarker remains controversial and no consensus has been reached.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Expression of Cyclin E in Gastrointestinal Cancer

Huang

Ren

Tang

et al. 2015

Technol Cancer Res Treat

View full text Add to dashboard Cite

Cyclin E is a critical regulator in cell cycle and promotes the initiation of DNA replication and centrosome duplication in late G1. The overexpression of cyclin E is common in cancers of the digestive system. However, whether cyclin E represents a prognostic biomarker in gastrointestinal cancer remains controversial. We reviewed the published literatures to clarify the association between cyclin E determined by immunohistochemistry (IHC) and survival in gastrointestinal cancer. Literatures were searched in PubMed and Cochrane Library published up to December 1, 2014. A total of 282 articles were initially identified, and 14 articles were included in this study. Meta-analysis was performed for 10 studies with a total of 1300 patients. Combined hazard risk (HR) and corresponding 95% confidence interval (CI) were calculated by random-effect model due to the heterogeneity. The quality of included studies was assessed by the Newcastle-Ottawa Scale and the Methodological Index for Non-Randomized Studies (MINORS). We found that high level of cyclin E was a predicator of poor prognosis among patients with gastrointestinal cancer (HR ¼ 1.67, 95% CI ¼ 1.06-2.63, P ¼ .028). In summary, overexpression of cyclin E is associated with poor prognosis in gastrointestinal cancer and expression of cyclin E determined by IHC might be a prognostic marker for gastrointestinal cancer in clinical practice.

show abstract

“…Following the failure of first-line chemotherapy, several drugs are recommended for second-line regimens, including paclitaxel, docetaxel and irinotecan (38). The median OS of patients receiving second-line docetaxel-based regimens ranges from 3.5 to 10.9 months, which is still dismal (5).…”

Section: Discussionmentioning

confidence: 99%

High BIM mRNA levels are associated with longer survival in advanced gastric cancer

Huang

Zou

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS). All 131 patients received first-line FOLFOX combination chemotherapy with folinic acid and 5-FU, in which 56 patients were further treated with second-line docetaxel-based chemotherapy. A correlation between the mRNA expression levels of BIM and AEG-1 was observed (r s =0.30; P=0.002). There was no association between the mRNA expression levels of any of the individual genes analyzed and OS in patients only receiving first-line FOLFOX chemotherapy. In a subgroup of patients receiving docetaxel-based second-line chemotherapy, those with high or intermediate levels of BIM exhibited a median OS of 18.2 months [95% confidence interval (CI), 12.8-23.6], compared with 9.6 months (95% CI, 8.9-10.3) in patients with low BIM levels (P=0.008). However, there was no correlation between the mRNA expression levels of AEG-1 or AXL and OS. The risk of mortality was higher in patients with low BIM mRNA levels than in those with high or intermediate BIM mRNA levels (hazard ratio, 2.61; 95% CI, 1.21-5.62; P=0.010). Therefore, BIM may be considered as a biomarker to identify whether patients could benefit from docetaxel-based second-line chemotherapy in GC.

show abstract

Medical management of gastric cancer: A 2014 update

Cited by 37 publications

References 64 publications

Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50

Analyzing Gastric Lavage of Gastric Cancer Patients: A Prospective Observational Study on Cytopathology and Determination of Intragastric CEA, CA 19.9, CA 72.4, and CA 50

Prognostic Value of Expression of Cyclin E in Gastrointestinal Cancer

High BIM mRNA levels are associated with longer survival in advanced gastric cancer

Contact Info

Product

Resources

About